Growth Hormone and Obesity

Astrid Hjelholt; Morten Høgild; Ann Mosegaard Bak; Mai Christiansen Arlien-Søborg; Amanda Bæk; Niels Jessen; Bjørn Richelsen; Steen Bønløkke Pedersen; Niels Møller; Jens Otto Lunde Jørgensen

doi:10.1016/j.ecl.2020.02.009

Growth Hormone and Obesity

Astrid Hjelholt, Morten Høgild, Ann Mosegaard Bak, Mai Christiansen Arlien-Søborg, Amanda Bæk, Niels Jessen, Bjørn Richelsen, Steen Bønløkke Pedersen, Niels Møller, Jens Otto Lunde Jørgensen^*

^*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

Abstract

Growth hormone (GH) exerts IGF-I dependent protein anabolic and direct lipolytic effects. Obesity reversibly suppresses GH secretion driven by elevated FFA levels, whereas serum IGF-I levels remain normal or elevated due to elevated portal insulin levels. Fasting in lean individuals suppresses hepatic IGF-I production and increases pituitary GH release, but this pattern is less pronounced in obesity. Fasting in obesity is associated with increased sensitivity to the insulin-antagonistic effects of GH. GH treatment in obesity induces a moderate reduction in fat mass and an increase in lean body mass but the therapeutic potential is uncertain.

Original language	English
Journal	Endocrinology and Metabolism Clinics of North America
Volume	49
Issue	2
Pages (from-to)	239-250
Number of pages	12
ISSN	0889-8529
DOIs	https://doi.org/10.1016/j.ecl.2020.02.009
Publication status	Published - 2020

Keywords

Growth hormone
Insulin-like growth factor I
Obesity

Access to Document

10.1016/j.ecl.2020.02.009

Cite this

@article{eb3746bdbe4a42c09bca638f7635c0a9,

title = "Growth Hormone and Obesity",

abstract = "Growth hormone (GH) exerts IGF-I dependent protein anabolic and direct lipolytic effects. Obesity reversibly suppresses GH secretion driven by elevated FFA levels, whereas serum IGF-I levels remain normal or elevated due to elevated portal insulin levels. Fasting in lean individuals suppresses hepatic IGF-I production and increases pituitary GH release, but this pattern is less pronounced in obesity. Fasting in obesity is associated with increased sensitivity to the insulin-antagonistic effects of GH. GH treatment in obesity induces a moderate reduction in fat mass and an increase in lean body mass but the therapeutic potential is uncertain.",

keywords = "Growth hormone, Insulin-like growth factor I, Obesity",

author = "Astrid Hjelholt and Morten H{\o}gild and Bak, {Ann Mosegaard} and Arlien-S{\o}borg, {Mai Christiansen} and Amanda B{\ae}k and Niels Jessen and Bj{\o}rn Richelsen and Pedersen, {Steen B{\o}nl{\o}kke} and Niels M{\o}ller and {Lunde J{\o}rgensen}, {Jens Otto}",

year = "2020",

doi = "10.1016/j.ecl.2020.02.009",

language = "English",

volume = "49",

pages = "239--250",

journal = "Endocrinology and Metabolism Clinics of North America",

issn = "0889-8529",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Growth Hormone and Obesity

AU - Hjelholt, Astrid

AU - Høgild, Morten

AU - Bak, Ann Mosegaard

AU - Arlien-Søborg, Mai Christiansen

AU - Bæk, Amanda

AU - Jessen, Niels

AU - Richelsen, Bjørn

AU - Pedersen, Steen Bønløkke

AU - Møller, Niels

AU - Lunde Jørgensen, Jens Otto

PY - 2020

Y1 - 2020

N2 - Growth hormone (GH) exerts IGF-I dependent protein anabolic and direct lipolytic effects. Obesity reversibly suppresses GH secretion driven by elevated FFA levels, whereas serum IGF-I levels remain normal or elevated due to elevated portal insulin levels. Fasting in lean individuals suppresses hepatic IGF-I production and increases pituitary GH release, but this pattern is less pronounced in obesity. Fasting in obesity is associated with increased sensitivity to the insulin-antagonistic effects of GH. GH treatment in obesity induces a moderate reduction in fat mass and an increase in lean body mass but the therapeutic potential is uncertain.

AB - Growth hormone (GH) exerts IGF-I dependent protein anabolic and direct lipolytic effects. Obesity reversibly suppresses GH secretion driven by elevated FFA levels, whereas serum IGF-I levels remain normal or elevated due to elevated portal insulin levels. Fasting in lean individuals suppresses hepatic IGF-I production and increases pituitary GH release, but this pattern is less pronounced in obesity. Fasting in obesity is associated with increased sensitivity to the insulin-antagonistic effects of GH. GH treatment in obesity induces a moderate reduction in fat mass and an increase in lean body mass but the therapeutic potential is uncertain.

KW - Growth hormone

KW - Insulin-like growth factor I

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=85083344829&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2020.02.009

DO - 10.1016/j.ecl.2020.02.009

M3 - Review

C2 - 32418587

AN - SCOPUS:85083344829

SN - 0889-8529

VL - 49

SP - 239

EP - 250

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

IS - 2

ER -

Growth Hormone and Obesity

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this